12th - 13th September, 2023
Sheraton Tower, Singapore (In-Person)



12th - 13th September, 2023
Sheraton Tower, Singapore (In-Person)






Abhishek Mathur
Abhishek Mathur is currently working as the Chief Scientific Officer at Biolexis Pvt Ltd (A Strides Group Company), and is based in Bangalore, India. At Biolexis, Abhishek is responsible for leading CMC, Regulatory and Clinical strategy for end-to-end development and commercialization of biological therapeutics with special focus on regulated markets. In the role, Abhishek is also responsible for identifying in-licensing opportunities for early phase biological products & product cell lines, and developing a robust product pipeline for Biolexis. Abhishek has over 16 years of experience in leading biologics development at top tier biopharma companies like Amgen and Regeneron in the USA. During his stints in these organizations, he has successfully led multiple novel Biologics & Biosimilar programs from preclinical stage through commercialization. Further, in these roles he also established and led several strategic external partnerships with several CDMOs across the globe. Abhishek holds PhD in Biological Sciences from Northwestern University (USA), Bachelors of Technology in Chemical Engineering from IIT Bombay (India) and an MBA from Duke University (USA).



Antiksha Joshi
Antiksha Joshi holds a Master’s degree in Microbiology from the Maharaja Sayajirao University in Gujarat, India. She began her professional journey in 1998 as a microbiologist but was soon fascinated by the world of Quality Management Systems and has spent the past 20+yrs working as a pharmaceutical/biotech Quality professional.
Her professional motto has always been “Quality without chaos”. This philosophy has guided her in successfully implementing Quality Management systems in different industries (from a large gelatin manufacturer to smaller biotech CDMO) and get employee buy-in to the concept of quality. Antiksha has successfully faced regulatory audits by the USFDA, MHRA, and the TGA. These experiences have furthered her love for Quality and the need for focussing on Quality Culture rather than compliance.
Antiksha is also a volunteer mentor in organisations that work with children and young adults. In her free time, Antiksha loves to read and go on long walks with her husband. She recently took a career break from her position as Head of QA at Luina Bio, Australia, to spend some time with her family.



Federica Fraschetti
Federica Fraschetti has spent her entire career in the Pharmaceutical Industry, developing an expertise in Manufacturing of Sterile Drug Product (DP) and Secondary Packaging at Contract Manufacturing Organizations (CMOs). In her current position at MSD, Federica is responsible for overseeing DP manufacturing operations for New Product Introductions, working across multiple CMOs . In her career, Federica hold various positions in the Operations field at Biogen, BMS and MSD and had extensive experience in Tech Transfer (TTs), managing Projects and overseeing Commercial Manufacturing at External Partners (EPs).
Federica holds a Masters in Biomedical Engineering from ETH Zürich, and a Bachelor degree in Clinical Engineering from La Sapienza University of Rome.
Today's MSD is a global healthcare leader working to help the world be well. MSD is a tradename of Merck & Co., Inc., Rahway, NJ., U.S.A. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.msd.com



Gerry McKiernan
Gerry has 20 years’ experience in various Quality roles in R&D and cGMP manufacturing in Europe, Asia and Australia and holds the accountability for the Quality Management System to deliver complex cell therapy products to patients on behalf of Cell Therapies Pty Ltd.
Gerry’s career has included biotechnology, pharmaceutical and medical device industries, where he was overseeing quality systems for product development, clinical trials, validation and contract manufacturing. He has led large Quality Management System implementation projects for cell therapy manufacturing in China and Japan and was the project lead for the commercial manufacturing licence approvals for Cell Therapies Pty Ltd for Australian and Asian markets.



H. Fai Poon
Dr. Poon is currently the President of Quacell Biotech Ltd. He previously worked for Hisun Biopharm, Merck (SAFC), Roskamp Institute in USA. He completed his Ph.D. in Biological Chemistry at University of Kentucky, and MBA from University of South Florida. He has years of experience in the field of biological therapeutics, analytical research, bioinformatics and proteomics. He has more than 10 years of cell culture experience with focus on biopharmaceutical products.
He published more than 30 peer-reviewed articles, and contributes to more than 5 book chapters. He is currently the managing editor for biomedical and pharmacology journal ; associate Editor for Journal of Chemistry, Biochemistry; and Molecular Biology, Band Journal of Bioinformatics and Biometrics.
Research Interest: Biotherapeutics; proteomics, metabolomics, cell line engineering, cell cultures, multivariate analysis, QbD, PAT.



Harshad Shete
Dr. Harshad Shete is professionally trained in the field of pharmaceuticals, particularly in injectables, complex injectables, topical and peptide-based dosage forms. Graduated with a PhD in Pharmaceutics from Institute of Chemical Technology (ICT) where he focused on Cationic Lipid Nanoparticles (LNP) based Nucleic acid delivery, Dr. Harshad Shete continued to pursue his post-doctoral studies with Texas A & M University, strengthening expertise in formulation of biodegradable polymer-based nanoparticles for delivery of peptides and anticancer molecules and more.
With more than 8 years of working across various functions, Dr. Harshad Shete’s stints with notable industry players such as Novartis, Sun Pharma Advanced Research Company Ltd. and Cipla further honed his skillsets and sharpened his industry knowledge in CMOs, from application, technical operations, technology transfer, manufacturing to commercialization. To date, he has two patents, seven publications of international repute and several awards to his credit.



Himanshu Gadgil
Dr. Himanshu Gadgil serves as the CEO at Enzene Biosciences Ltd. Under his services, Enzene has grown from a start-up biotech to a multi-vertical, multi-site product development and manufacturing service based biopharmaceutical company. Prior to Enzene, he worked as the Sr. Vice President at Intas Pharmaceutical Ltd. where he was instrumental in turning around the commercial product pipeline by launching several biosimilar products in multiple geographies. During his stint in the US, he led different facets of process and product development at Amgen spearheading IND, BLA and Market authorizations of various blockbuster biotech products. At the inception of his career, he joined Waters Corporation where he pioneered development of QBD enabling multi-attribute methodologies for biopharmaceutical characterization. Himanshu holds a PhD in Biochemistry from University of Tennessee and is a passionate scientific leader as well as innovator with over 50 publications and patents.



Jincai Li
Dr. Jimmy Li is currently CEO of WuXi XDC, a dedicated, fully integrated bioconjugation CDMO, a subsidiary of WuXi Biologics. Prior to this, Dr. Li joined WuXi Biologics in 2011 and helped built and led the Cell Culture Process Development & Pilot Plant Production group, and later managed the MFG1, MFG3 cGMP facilities, as well as the start-up of the MFG5 facility. Dr. Li has 20 years’ experience in biologics process development, scale-up and cGMP manufacturing. His group contributed to over 40 IND submissions, both in and outside of China, as well as multiple BLA submission works. During his tenure with MFG1, Dr. Li led the efforts to successfully pass the company’s first FDA and EMA pre-license inspections (PLI), achieving the first FDA biologics BLA approval for China.
Before, Dr. Li was Group Leader at Genentech Inc, where he led a group responsible for cell culture process development. Before Genentech, Dr. Li also worked at Tanox, Inc, and at Diversa Corporation (now BASF), in charge of process development for multiple biologics projects.



Kitipong Uaesoontrachoon
Dr. Uaesoontrachoon has been involved in the gene therapy field for more than a decade, starting with the neuromuscular diseases. Under his guidance, promising therapies have either entered into various phases of clinical trials or received accelerated approval for use by The Food and Drug Administration (US FDA). He received his PhD in molecular and cellular biology from the University of Melbourne, Australia and post-doctoral training in the laboratories for genetic medicines at Children’s National Medical Center, Washington, DC. He held an Adjunct Professorship in Department of Pharmacology at Dalhousie University, Halifax, Canada, and served as the Principal Director of Research at AGADA Biosciences overseeing their entire pre-clinical trials and clinical testing operations. Currently, he holds a Chief Scientific Officer position at Genepeutic Bio, a CDMO specializing in manufacturing CAR-T cells for treatment of various forms of cancer but also has its own pipeline.



Lucas Chan
Dr. Lucas Chan is the Chief Scientific Officer of CellVec in Singapore, a CDMO dedicated to the development and manufacture of viral vectors for human gene therapy. Lucas received his PhD at Imperial College London and was a Senior Investigator and Head of Manufacture for Advanced Therapies at King’s Health Partners in London, where he led translational development of several Advanced Cell and Gene Therapies for clinical development and established UK’s first contract manufacturing capability for clinical grade viral vectors. He is an elected Fellow of the Royal Society of Biology and an advisory member on Cell and Gene Therapy regulations in Singapore.



Mahesh Bhalgat



Manimaran Ulaganathan
Mr Manimaran is having 16 years of R&D lab experience in the Biotech industry, and he is associated with Waters India for 2 years. He has actively supported Biopharma customers across India on LC and MS applications. Experienced in Biopharma with hands-on experience in Mass Spectrometry, Chromatographic and other analytical techniques.



Narasimha Nedunuri
Narasimha Rao Nedunuri is one of the founding members of CLONZ Biotech, a 11 year old Clinical stage Biosimilar Monoclonal Antibody start-up company based in Genome Valley, Hyderabad, India. Nedunuri, a Molecular Biologist turned Entrepreneur has 2 decades of experience in the field of Life Sciences Research including Cancer Biology, Proteomics, and Molecular diagnostics. Nedunuri is one of the members of CII India Biotech Committee and also Mentoring yound Entrepereneurs at Incubation Centres. Nedunuri at CLONZ , along with the co-promoters coming from recognized leaders ,currently driving the company as the Managing Director.



Nares Damrungchai
For over 25 years, Dr. Nares have been a leader in the life sciences space. He was the Executive Director of the APEC Center for Technology Foresight, the Lead Shepherd of the APEC Industrial Science and Technology Working Group, and recently Co-Chair of APEC Life Sciences Innovation Forum between 2014-2020.
Dr. Nares was invited to join an International Expert Panel for Asia-Paci!ic in the creation of the Personalised Health Index, an ambitious project attempting to benchmark healthcare data from countries across the globe.
In Thailand, his home country, Dr. Nares served for two full terms as CEO of the Thailand Center of Excellence for Life Sciences (TCELS), where he helped creating a robust life sciences cluster in the country. For this, he received the Royal Thai Government Scholarship Award for Outstanding Alumni in 2017.
Since 2021 have been with Genepeutic Bio, a biotech company focusing on developing next-generation cell and gene therapies, where he currently serves as the Chief Advisor



Paul Mcdonald
Paul McDonald is a Pharmaceutical Manufacturing and Development Executive with, in excess of 25 years in the sector. Paul has particularly focussed in the areas of development and delivery of pharmaceutical product pipelines, contract manufacturing and manufacturing quality. Paul has held senior management roles at Pfizer, Hospira and IDT Australia. Paul’s qualifications include formal studies in Chemistry, Biomedicine and Business.



Prateek Gupta
Prateek is currently serving as Vice President and Head of Technical Development & MSAT at Stelis Biopharma, an integrated biopharmaceutical CDMO based out of India. In this role, he provides overall leadership for delivering high-value biopharmaceutical development services for global customers and is responsible for building strategic growth plans and capabilities to maintain a robust project pipeline. Prateek is passionate about developing and manufacturing high quality affordable biologics and vaccines and contributing to improved access to patients worldwide.
Prateek has over 15 years of experience, including international leadership roles in biopharmaceutical companies (Genentech and Pfizer) as well as academic institutions, in the development and manufacturing of novel biologics as well as biosimilars. His academic pedigree includes PhD from Cornell University and a dual degree (B. Tech and M. Tech) from IIT Delhi.



Sethu Madhavan Sankaran
Sethu Madhavan has over 25 years of documented accomplishments spanning multiple industries (Petrochemical, Pharma/Biopharma Technology), companies of all sizes(1000-40,000 employees) and in Global multisite, multi culture environments.
Currently he is Vice President – Global Head Insulin Operations,Biocon Biologics Ltd. He is responsible to build and Position operations for growth and eventual scaling, with goal of returning strong profits to shareholders; Responsible for 2 manufacturing sites (One each In india and Malaysia) and all operations includingTech ops.
He has done his Masters in Patent law (2011) Nalsar University Hyderabad; Master’s in Business Administration ( Fin &Strategy ), MDI, Gurgaon; Master of Chemical Engineering, University Institute of Chemical Technology ,Mumbai



Thomas Yuan
Before founding TFBS in 2016, Dr. Yuan was Vice-President of Development Center of Biotechnology (DCB) in Taiwan,responsible for drug discovery and development. During his 12-year tenure at DCB, Dr. Yuan had leadership roles overvarious research activities from drug design, assay development, pharmacology, to preclinical development. Prior tojoining DCB, Dr. Yuan assumed research positions in the HCV Group at Roche Pharmaceutical in Palo Alto, and in theGene Therapy Division of Berlex Bioscience in Richmond, California. Dr. Yuan has completed his academic training as apostdoctoral fellow at University of Texas, Medical Branch in Galveston, after obtaining a doctorate degree inBiochemistry from University of Pennsylvania.



Weiran Shen
Dr. Shen is the vice president of R&D department in OBiO Technology. He leads vector design, innovation, novel vector development, stable and producer cell line selection, in vitro/vivo model construction and improves potency-cost ratio in GCT products by virological and cellular mechanistic designing. Dr. Shen also works on R&D related activities including patent application, customer service, scientific and business partnership, new product development, global market expansion and beyond.
Before joining OBiO Technology, Dr. Shen took positions of group lead, scientist, associated director and director in both academia and industry settings. His experience covers novel vector design and construction, pipeline selection and development, target selection and validation. He established research vector core and multiple analytical and bioanalytical assays for research use. He coordinated and had been involved in dozens of nonclinical pipelines, high-throughput sequencing and data analysis, AI guided capsid engineering, small and large animal model evaluation, histopathological data analysis, immune responses analysis, and activities in analytics and bioanalytic, partnership, business due diligence, patent scoping and legal evaluation. He published 16 peer reviewed articles, with another 2 under preparation, 1 book on popular science, 6 provisional patents, multiple international conference oral presentations, abstracts and posters.
Dr. Shen has master of science degree in Neuroscience and doctor degree in Microbiology. He has specific contributions to parvovirus replication, viral-host interaction, the challenges and potential solutions to viral vector application in gene and cell therapy field.



Zack Zheng
Dr. Zack Zheng, CTO and SVP, R&D of Chime Biologics, taking fully responsibility for the process development, technology transfer and scale-up, protein science and research, and Shanghai innovation center.
Dr. Zheng has 25 years broad experience in biopharmaceutical industry to develop therapeutic protein,antibody drugs and vaccines in USA and China. His expertise spans from process development, technology transfer to cGMP production. He is a CMC leader with experience to develop both biosimilar and innovator drugs, and has brought multiple biologic products to market.
Previously Dr. Zheng is the co-founder and VP of DZM Biotech and VP of Jecho Biopharma. Before returning back to China 10 years ago, he held several technical and management positions as principal scientist and project manager in MedImmune, Wyeth, Pfizer with increased responsibilities.
Dr. Zheng received his bachelor degree in chemistry from Beijing Normal University, Ph.D. in chemistry from Nankai University, and did his postdoctoral training in Department of Chemistry, Aarhus University, Denmark and Department of Chemistry and Biochemistry, University of Delaware, USA.


The global demand for Contract Manufacturing Organizations (CDMO) is expected to benefit from the outbreak of the Coronavirus pandemic. The contract manufacturing company segment is anticipated to open up lucrative business growth opportunities. The global CMO market is expected to hit US$241.3 billion in 2024, with a compound annual growth rate (CAGR) of 9.80 percent from 2020 to 2024.
In Asia's biopharmaceutical contract manufacturing industry, the biologics segment had the largest market share in 2020. The contract manufacturing of biologics has seen a big uptick. This is due to difficulties in producing large-scale biologics on a small scale in-house. Sanofi, for example, has hired Boehringer Ingelheim to produce its biologics pipeline. Many organizations are turning to CMOs to expedite the development process and reduce production costs. These markets demonstrate and witness growth at a significant rate in the Asia region.



Croda Pharma is a leading partner for the development of excipients and the supply of high purity materials for pharmaceutical formulations, committed to enabling the next generation of drug delivery systems.
The business is focused on empowering biologics drug delivery, through its adjuvant systems, small molecule, protein, and nucleic acid delivery platforms. With a wide range of solutions for both human and animal health markets, our pharmaceutical portfolio is unsurpassed in its excellence for drug and vaccine delivery.
Croda’s products, along with its in-house formulation and regulatory expertise, allow the business to meet its customers’ most demanding formulation needs.
The company also recently celebrated winning the prestigious “Best Supplier for COVID-19 Vaccine Development” at the India Biologics & Vaccines Outstanding Industry Awards (BVOIA) 2022. The awards give recognition to exceptional biologics and vaccine experts, and technologies that facilitate R&D and biologics manufacturing excellence.
To learn more about what Croda Pharma offers, visit us at: www.crodapharma.com



Waters Corporation unlocks the potential of science through analytical measurement technology, deep scientific expertise, and reliable insights to enhance human health and well-being. As a global provider of analytical technology, Waters makes scientific ambitions a reality through the application of liquid chromatography, mass spectrometry and thermal analysis instruments, consumables, and informatics as well as industry-leading scientific expertise. For over 60 years, the company has distributed its products globally to a variety of industries, including pharmaceuticals, chemicals, food, environmental, forensic toxicology, biomedical research, and clinical diagnostics. With more than 7,400 employees worldwide, Waters operates in 35 countries, including 14 manufacturing facilities, with products available in more than 100 countries.



MasterControl Inc. is the leading provider of cloud-based quality and compliance software for life sciences and other regulated industries. Our mission is the same as that of our customers – to bring life-changing products to more people sooner.
You can use the MasterControl Product Lifecycle Excellence™ platform to digitize, automate and connect quality and compliance processes at every step – from concept to commercialization. Join over 1,000 companies worldwide that rely on MasterControl solutions to achieve new levels of operational excellence across product development, clinical trials, regulatory affairs, quality management, supply chain, manufacturing and postmarket surveillance.
Learn more at www.mastercontrol.com



Stelis Biopharma Limited (Stelis) is a fully integrated pure-play biologics Contract Development and Manufacturing Organization (CDMO), offering the complete spectrum of services, from cell line technology transfer to clinical and commercial manufacturing with capabilities to convert drug substance into stable formulations and fill and finish formats. With proven technical expertise in microbial, mammalian, viral vectors, and various other technology platforms with world-class cGMP manufacturing facilities that offer high-quality services for your global programs.
Stelis has three state-of-the-art facilities, with ~85,000 sqm of area house process development laboratories, scale-up, and manufacturing areas for mammalian, microbial and other modalities. The company’s highly automated facilities provide global services for products based on Monoclonal antibodies, Fusion proteins, Conjugation factors, Vaccines, Cell-free protein expression platforms, DNA adjuvants/plasmids, RNA products, Cell and gene therapy, and all other types of biologics, biosimilars and vaccines. It’s agility in building capacities, increasing accuracy, efficiency and speed at every stage of process development and manufacturing processes is unparalleled.
Stelis, over the years, has built a robust CDMO platform. Offers large drug substance capacities of over 48,000L across various modalities and drug product capacities exceeding 400 million units per annum. The company has the capabilities to deliver your projects from clinical to commercialization with best-in-class facilities capable of delivering any scale of production volumes with agility to expand capacities at industry-leading speed. With 48,000L of drug substance capacities across multiple modalities, Stelis is one of the largest CDMOs in the Asia-Pacific (APAC) region.
The company’s experienced quality and regulatory personnel help meet the highest global quality standards, ensure compliance and guide it’s clients through the regulatory approval. The large-scale commercial use facilities were designed with consultation from international regulatory agencies, including the USFDA, and a holistic and systematic approach to building and sustaining the Stelis Quality Culture.
For more information, visit www.stelis.com.



TFBS Bioscience Inc. is a certified and leading GMP Viral Vector Contract Development and Manufacturing Organization in Asia-Pacific and the first specialist viral vector provider in Taiwan.



Novartis Global Biotech Cooperations is a Contract Development and Manufacturing Organization that helps customers around the world produce and manufacture life-changing biotechnological products – always meeting the highest standards in quality and regulatory compliance. Our capabilities ranges between Plasmid DNA, RNA, Cell & Gene Therapy, Microbial Manufacturing, Mammalian Cell Culture, Fill & Finish, Viral Vector and other innovative technologies. We’re a global team of scientific, economic and manufacturing experts, supported by Novartis – a company with over 40 years’ experience in biologics manufacturing.
https://www.novartis.com/



Marken is a wholly owned subsidiary of UPS and is a critical part of UPS Healthcare. With Polar Speed and Marken included, the UPS Healthcare division staffs 128 locations with 5,500 employees worldwide. Marken offers a state-of-the-art GMP-compliant depot network and logistic hubs for clinical drug product storage and distribution in 59 locations worldwide, while maintaining the leading position for Direct-to-Patient and Home Healthcare services, biological sample shipments and biological kit production.
Marken’s dedicated 2,000 staff members manage 135,000 drug product and biological sample shipments every month at all temperature ranges in more than 220 countries and territories and have orchestrated 11,500+ home healthcare visits. Additional services such as cell and gene supply chain services, ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy add to Marken’s unique position in the pharma and logistics industry.
Website: https://www.marken.com/



With over 35 years’ experience as a global contract service organization, SGS provides integrated (bio)pharmaceutical development and testing solutions including clinical research, pharmaceutical development, biologics characterization, biosafety, and quality control testing for small and large molecules, raw materials, containers and finished products.
SGS provides a comprehensive range of biosafety services such as: virology, cell and molecular biology, microbiology and TEM. Health Authorities (US FDA and the EMA), require companies to undergo safety testing demonstrating that cell banks, viral banks, raw materials, bulk harvests, and batches of clinical drug are free of bacteria, fungi, mycoplasma, viruses and other potential contaminants. SGS ensures product safety in satisfying these regulatory requirements.



Pfanstiehl is the market leader of high purity, low endotoxin, low metal excipients for biologics, biosimilars, vaccines, cell culture media and injectable (liquid and lyophilized) formulations and supplies its products to nearly all leading global biopharmaceutical companies.
Pfanstiehl was founded in 1919 and currently celebrating its 103rd anniversary year in 2022. Pfanstiehl is headquartered at Waukegan, IL, USA and has diverse global technical support team across the globe in USA, Europe & APAC.
Pfanstiehl has manufactured parenteral grade excipients for more than 50 years, and Pfanstiehl’s high purity, low endotoxin and low metal excipient products are known as “best in class” due to their high characterization, performance, consistency, and quality attributes.
Pfanstiehl’s excipients are critical components in the majority of the global blockbuster biopharmaceutical drugs and vaccines including majority of the Covid -19 vaccines that were administered globally.
For more information about Pfanstiehl Inc, and their products and solutions, please contact us at [email protected] or visit www.Pfanstiehl.com”







Catch the latest in Asia-Pacific's contract manufacturing sector. From current best practices to advancing towards SMART manufacturing, from recent most-exclusive case-studies to industry's key needs. All this and more under 1 roof!
Leadership Panel Discussion by APAC Leaders: Extensive Insights Into The Biologics Contract Manufacturing Market
GMP Manufacturing Requirements and Processes
Accelerate Manufacturing Processes To Reduce Cost And Expedite Timelines
SMART Manufacturing: Bioprocessing 4.0
Biologics CMO/CDMO Case Studies & Facility Overview from APAC
Best Practices to Mitigate Supply Chain Disruption






Asia Pacific Biologics CMO & CDMO Excellence Awards 2022
Asia Pacific Biologics CMO & CDMO Excellence Awards 2022 seeks to give recognition to exceptional CMO & CDMO that facilitate biologics manufacturing excellence at enhanced speed, reduced cost, and superior quality from the biologics contract manufacturing space.Featuring top CMO/ CDMO leaders in the industry, along with the latest advances in technologies and best practices in biologics R&D and manufacturing, the Asia Pacific Biologics CMO & CDMO Excellence Awards 2022 applauds extraordinary leaders & trend-setters of today and inspires innovators of tomorrow.


Biologics CMO Pavillion 2022
Biologics CMO Pavilion 2022 aims to feature the CMOs from the Asia Pacific Region to showcase the services/solutions from their companies and represent their countries at this pavilion.
At the Pavilion we are limiting one representative CMO organisation from each country and hence make it very exclusive.
The Pavilion will provide an opportunity to generate business leads for companies and help promote themselves. Some important features at the pavilion include the strategic location of the booths and limited edition representation from their countries. Also the CMO booth would add more value to the exhibitors as the event is co-located with the 6th Annual Cell & Gene Therapy World Asia conference along with the Biologics Contract Manufacturing Asia conference which deep-dives into the fast evolving Contract Manufacturing sector in the region.
Limited Super Access - End User (CMOs Headquarter Located in ASIA)
- 2-Day Conference Access
- Sale Ends 10th March 2023 | Midnight
Limited Super Access - Vendor/BD/MKT (CMOs Headquarter Located Outside of ASIA)
- 2-Day Conference Access
- Sale Ends 10th March 2023 | Midnight


It's my pleasure to be a participant in IMAPAC's 11th World Vaccine Summit. This virtual platform supported in exploring more on the current trends on vaccine developments from various manufacturers/ research centters






Excellent event with with good knowledge-sharing by experienced scientists globally to combat present situation and challenges faced by the vaccines manufacturing industry. Kind hospitality by IMAPAC...Keep it up.






Talks were very interesting addressing subjects really important such as the balance of Th1 and Th2 cells as immune response of COVID-19 vaccines. I watched a lot watching and rewatching the videos too.











Present your expertise to the key vaccines stakeholders from developing economies through a variety of available speaking packages.
Join the exhibition, and build an impressive presence among your potential clients.
Emphasize on your messages by promoting your brand alongside exhibition and thought leadership.
Engage with and build lasting connections that matter the most to your business.
Gain exclusive access to contacts of high-profile attendees through intimate networking opportunities.